- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Botanix Pharmaceuticals Ltd (BOT)
Botanix Pharmaceuticals Ltd stock price live, this page displays ASX BOT stock exchange data. View the BOT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Botanix Pharmaceuticals Ltd real time stock price chart below.
What Is the Botanix Pharmaceuticals Ltd Stock Price Today?
The Botanix Pharmaceuticals Ltd stock price today is 0.023.
What Is the Stock Symbol for Botanix Pharmaceuticals Ltd?
The stock symbol for Botanix Pharmaceuticals Ltd is "BOT."
What Stock Exchange Does Botanix Pharmaceuticals Ltd Trade On?
Botanix Pharmaceuticals Ltd is listed and trades on the Sydney stock exchange.
Is Botanix Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Botanix Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BOT quote. (ISIN: AU000000BOT2)
What Is the Botanix Pharmaceuticals Ltd Stock Price Today?
The Botanix Pharmaceuticals Ltd stock price today is 0.023.
What Is the Stock Symbol for Botanix Pharmaceuticals Ltd?
The stock symbol for Botanix Pharmaceuticals Ltd is "BOT."
What Stock Exchange Does Botanix Pharmaceuticals Ltd Trade On?
Botanix Pharmaceuticals Ltd is listed and trades on the Sydney stock exchange.
Is Botanix Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Botanix Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BOT quote. (ISIN: AU000000BOT2)
Sydney
Currency in AUD
0.023
0.000(0.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.022
0.024
52 wk Range
0.018
0.170
BOT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.0220.024
52 wk Range
0.0180.170
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
BOT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
0.490
Upside
+2,030.43%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 0.490
(+2,030.43% Upside)
Botanix Pharmaceuticals Ltd Earnings Call Summary for Q4/2026
- Q4 FY2026 net revenue rose 45% sequentially to $10.1M; prescription shipments increased 25% to 33,900 units as demand for Sofdra grew.
- Operating cash outflow fell 54% to $10.6M from $23.3M in Q3; gross-to-net yield improved to 22% from 18% prior quarter.
- Company completed sales force optimization expected to reduce operating costs by 12% starting July 31, 2026, targeting 39 high-performing territories.
- Botanix pursuing secondary API supplier to cut cost of goods 25-40%; technical transfer with Piramal underway, completion expected in 6-9 months.
- 100% of surveyed prescribers expect to maintain or increase Sofdra use; shares fell 4.35% to $0.022 despite strong operational momentum.
Last Updated: 2026-07-26, 09:52 p/m
Read Full TranscriptEarnings
Latest Release
Apr 28, 2026
EPS / Forecast
-- / --
Revenue / Forecast
6.9M / 8M
Compare BOT to Peers and Sector
Metrics to compare | BOT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBOTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.7x | −3.7x | −0.4x | |
PEG Ratio | 0.01 | 0.14 | 0.00 | |
Price/Book | 1.2x | 5.6x | 2.6x | |
Price / LTM Sales | 2.9x | 22.8x | 3.0x | |
Upside (Analyst Target) | - | 46.5% | 48.7% | |
Fair Value Upside | Unlock | −2.0% | 5.6% | Unlock |
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the treatment of papulopustular rosacea; and BTX 1204A for treating atopic dermatitis. The company was incorporated in 1984 and is based in Melbourne, Australia.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Botanix Pharma (BOT) Stock Price Today?
The Botanix Pharma stock price today is 0.023 AUD.
What Stock Exchange Does Botanix Pharma Trade On?
Botanix Pharma is listed and trades on the Sydney Stock Exchange.
What Is the Stock Symbol for Botanix Pharma?
The stock symbol for Botanix Pharma is "BOT."
What Is the Botanix Pharma Market Cap?
As of today, Botanix Pharma market cap is 62.890M AUD.
What Is Botanix Pharma's Earnings Per Share (TTM)?
The Botanix Pharma EPS (TTM) is -0.046.
When Is the Next Botanix Pharma Earnings Date?
Botanix Pharma will release its next earnings report on Aug 28, 2026.
From a Technical Analysis Perspective, Is BOT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Botanix Pharma Stock Split?
Botanix Pharma has split 1 times.
How Many Employees Does Botanix Pharma Have?
Botanix Pharma has 11 employees.
What is the current trading status of Botanix Pharma (BOT)?
As of Aug 08, 2026, Botanix Pharma (BOT) is trading at a price of 0.023 AUD, with a previous close of 0.023 AUD. The stock has fluctuated within a day range of 0.022 AUD to 0.024 AUD, while its 52-week range spans from 0.018 AUD to 0.170 AUD.
What Is Botanix Pharma (BOT) Price Target According to Analysts?
The average 12-month price target for Botanix Pharma is 0.490 AUD, with a high estimate of 1 AUD and a low estimate of 0.14 AUD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +2,030.43% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.